Search results
Found 61759 matches for
A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim has been announced to investigate a new drug target for the treatment of schizophrenia.
Ilina Singh
NEUROSCIENCE, ETHICS AND SOCIETY THEME LEAD Ilina Singh - Professor of Neuroscience & Society
Keith Hawton CBE
DSc., DM, FRCPsych, FMedSci. Keith Hawton CBE - Emeritus Director, Centre for Suicide Research
Charles Newton
MBChB (UCT), MA (Oxford), MRCP (London), MD (UCT), FRCPCH Charles Newton - Cheryl & Reece Scott Professor of Psychiatry
Elizabeth Tunbridge
B.Sc. M.Sc. D.Phil. Elizabeth Tunbridge - Director of Translational Neuroscience, Boehringer Ingelheim
John Gallacher
PhD AFBPsS CPsychol FFPH John Gallacher - Professor of Cognitive Health; Director, Dementias Platform UK; Director, BrainWaves study of adolescent wellbeing and mental health